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Abstract
We have developed an efficient chemoenzymatic synthesis of heparan sulfate oligosaccharides
employing the para-nitrophenyl (p-NP) β-glucuronide as an acceptor compatible with enzymatic
elongation and one that significantly simplifies oligosaccharide purification on C-18 resin.
Employing ceric ammonium nitrate as oxidative reagent to remove the p-NP group unexpectedly
also removed the glucuronic acid residue at the reducing-end, affording a smaller oligosaccharide.
The application of ceric ammonium sulfate allowed the removal of the p-NP without concomitant
loss of the adjacent glucuronic acid offering a route to longer heparin sulfate oligosaccharide
products.
Keywords
Heparan sulfate oligosaccharides; chemoenzymatic synthesis; para-nitrophenyl glucuronic acid;
ceric ammonium salt; deprotection
Introduction
Heparan sulfate (HS) and heparin (HP) which belong to the family of glycosaminoglycans
(GAGs) are composed of (1→4)-linked alternating glucosamine and uronic acid residues
containing diverse substitution with O-sulfo, N-acetyl and N-sulfo groups.1 HS, which has
ubiquitous distribution on the cell surface and in the extracellular matrix, contains more
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varied structure but less sulfo groups than does heparin.2 HS/HP GAGs play important roles
in several physiological processes at the cell–tissue–organ interface including cell adhesion,
enzyme regulation, cytokine action, and the most convincing anticoagulation, etc.3 HP
widely used as an clinical anticoagulant is mainly used in the forms of unfractionated
heparin (UFH), low molecular weight heparins (LMWHs) and the synthetic ultralow
molecular weight heparins (ULMWHs), such as the drug known as Arixtra.4
Chemical synthesis of oligosaccharides, which includes construction of building blocks,
stereo- and regioselective glycosylation and deprotection steps, etc., has becoming more and
more critical to obtain pure substances for developing structure-activity relationships.5
However the chemical synthesis requires a large number of complicated steps, many that are
low yielding and challenging purification of both intermediates and products.
Chemoenzymatic synthesis of oligosaccharides represents a relatively more efficient
approach to obtain diverse targets.6 In our previous work, 10-step and 12-step
chemoenzymatic syntheses afforded two structurally homogeneous ULMWHs (molecular
mass = 1778.5 and 1816.5) in 45% and 37% overall yield, respectively.7
Although recent advances in chemoenzymatic synthesis have made the construction of
complex heparin-like oligosaccharide increasingly feasible,8 speeding up the purification
procedure after each enzymatic reaction was still necessary to obtain pure oligosaccharide
targets in a shorter time and in higher overall yields. The p-NP group is an ultraviolet
detectable, hydrophobic tag that can be reversibly bound to reversed phase chromatography
resins.9 C-18 silica resin was useful for purifying p-NP glycosides of oligosaccharides of
various sizes. After the final purification step the p-NP tag needed to be cleaved from the
product to achieve our final desired oligosaccharide target. However, general and practical
methods for deprotection of p-NP group are not well established, even though some
successful examples have been reported on the protected sugar substrates10 or the similar
substrates taged with p-nitrobenzyl (p-NPM), p-methoxybenzyl (p-MPM) and p-
pivaloylaminobenzyl (p-PAB) groups.11 In this communication, we examined the oxidative
deprotection of p-NP group with cerium reagents under mild oxidative conditions.
The chemoenzymatic synthesis of HS oligosaccharide backbones based on the p-NP β-
glucuronide (p-NPG, 1) is presented in Scheme 1. The strong UV absorbance and highly
C-18 binding affinity of the p-NP group greatly simplifies the process of oligosaccharide
purification. To construct the heparin oligosaccharide backbone, p-NPG 1 acceptor was
incubated with uridine diphosphate (UDP)-N-acetylglucosamine (GlcNAc) or UDP-N-
trifluoroacetyl glucosamine (GlcNTFA) donor and KfiA (N-acetylglucosaminyl transferase),
expressed in Escherichia coli K5, at room temperature overnight to furnish the disaccharide.
Next, the disaccharide was treated with UDP-glucuronic acid (GlcA) and pmHS2
(heparosan synthase-2), from Pasteurella multocida, and incubated for 4–5 h, followed by a
second addition of UDP-GlcA and pmHS2 to drive the enzymatic reaction to completion.
During both enzymatic reactions, high performance liquid chromatography (HPLC) on C18
silica column was used to monitor the consumption of acceptor and smooth generation of
products. Alternatively, while thin layer chromatography (TLC) could also be employed to
monitor the enzymatic reaction it required ten-fold more sample for detection.
Trisaccharides 2 and 3, with p-NP group at the reducing-ends, were obtained after a flash
chromatograhy on a reverse phase C-18 column. Another cycle of enzymatic reaction was
carried out to construct the tetrasaccharide and pentasaccharide (Scheme 1). Reversed phase
C-18 flash column was again performed in preparative scale to obtain sufficient
pentasaccharide 4 and 5 backbone structures for further modification.12
With these substrates in hand, we next explored the oxidative deprotection of p-NP group
using ceric ammonium nitrate (CAN). Conversion of nitro group, on the p-NP on
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trisaccharide 2, to an acetamido group on was first carried out by the hydrogenation with
Pd(OH)2/C in THF-H2O-acetic anhydride (4 : 5 : 1) furnishing the corresponding
acetamidophenyl glycoside. We found that the intermediate with a free aminophenyl group
was extremely sensitive to polymerization, so the freshly prepared acetic anhydride solution
was added to quickly and quantitatively convert the amino intermediate stable
acetamidophenyl glycoside. Oxidative cleavage reaction using 5 eq. of CAN at 0 °C for 30
min in water solution was based on the reported cleavage of the similar p-methoxyphenyl
group.11 However, a yield of less than 5%, detected by LC-MS, of desired trisaccharide was
observed. Instead, an unexpected disaccharide was obtained in 80% yield and its structure
was confirmed, using MS and NMR, to be missing the reducing-end GlcA residue. A similar
reaction was observed when the tetrasaccharide or pentasaccharide was treated under the
same conditions, affording the corresponding trisaccharide and tetrasaccharide with loss of
the reducing-end GlcA (Scheme 2.) Thus, CAN-mediated oxidation removed the entire p-
NPG not just the p-NP group.
The UDP-GlcNTFA donor was used to prepare a more structurally complex oligosaccharide
that could be deprotected using triethylamine and N-sulfonated using recombinant N-
sulfotransferase to furnish HS hexasaccharide 9 (Scheme 3).13 The CAN-mediated oxidative
approach was applied on 9 and expected to afford a relatively pure pentasaccharide after size
exclusive chromatography. Unfortunately, no pentasaccharide or hexasaccharide was
obtained on oxidative reaction with CAN. Therefore, we decided to the investigate
deprotection using the milder oxidative reagent, ceric ammonium sulfate (CAS), with a
lower reduction potential of +1.44 V (versus the normal hydrogen electrode) than the +1.61
V for CAN.14 On treatment with 5 eq CAS at 0 °C, hexasaccharide 10 was oxidized to
afford the product 11 in ~90% yield after column purification (Scheme 3).15 Thus, the
milder oxidative reaction with CAS proceeded smoothly removing the p-NP group without
the loss of the reducing-end GlcA, affording only the desired hexasaccharide backbone.
1D and 2D NMR spectroscopy of substrate 9 and HS hexasaccharide 11 clearly support the
mild nature of the oxidative deprotection of the p-NP group with CAS, (Figure 1).16 The
aromatic protons of intermediate 10 appear as doublets at 7.27 and 7.05 ppm in 1H NMR
and are distinguished from the signals 8.14 and 7.11 ppm of the substrate 9, confirming the
successful hydrogenation of nitro group. The disappearance of signals in aromatic region
of 1H NMR after CAS treatment clearly demonstrates the deprotection of the aryl group.
The anomeric protons on each sugar unit were assigned based on the 2D 1H-1H correlation
spectroscopy (COSY) and 1H-13C heteronuclear single quantum coherence (HMQC)
spectroscopy and the stereochemistry on glycosidic bond was confirmed through the
analysis of 1JCH on each anomeric carbon atom. TLC analysis (HCOOH/BuOH/H2O, 4/8/1)
also confirmed the reduction and removal of the p-NP group.
Further experiments were carried out to investigate whether the deprotection of p-NP group
with CAS could smoothly occur without removal of the reducing-end GlcA on other
oligosaccharides as well. Similar results were observed in the cases of oxidative p-NP
deprotection of compounds 2 and 4 with CSA, affording the corresponding trisaccharide 12
and pentasaccharides 13 in relatively high yields (Scheme 4). Further studies will be
required to determine how the oxidative reactivity of the p-NP group is impacted by
oligosaccharide size and the number and position of N-acetyl or N-sulfo groups within p-NP
tagged oligosaccharides.
Conclusions
The HS hexasaccharide was successfully synthesized through a chemoenzymatic approach
employing a p-NPG acceptor in which the p-NP group serves as a CAS removable tag. This
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protection/deprotection strategy should allow the construction of more structurally complex
and highly sulfated HS oligosaccharides and ULMWHs. These targets are currently viewed
as potential therapeutic agents for the modulation of anticoagulant and antithrombotic
activities. The successful application of oxidative deprotection reaction using CAS supplies
also provides a milder alternative for the deprotection of other sensitive substrates.
Acknowledgments
This work was supported by the National Institutes of Health in the form of grants HL62244, GM38060, and
HL094463.
References and notes
1. a) Sasisekharan R, Venkataraman G. Curr. Opin. Chem. Biol. 2000; 4:626–631. [PubMed:
11102866] b) Bishop JR, Schuksz M, Esko JD. Nature. 2007; 446:1030–1037. [PubMed:
17460664] c) Laremore TN, Zhang F, Dordick JS, Liu J, Linhardt RJ. Curr. Opin. Chem. Biol.
2009; 13:633–640. [PubMed: 19781979]
2. Salmivirta M, Lidholt K, Lindahl U. The FASEB Journal. 1996; 10:1270–1279.
3. Capila I, Linhardt RJ. Angew. Chem. Int. Ed. 2002; 41:391–412.
4. a) Linhardt RJ, Liu J. Current Opinion in Pharmacology. 2012; 12:217–219. [PubMed: 22325855]
b) Sommers CD, Ye H, Kolinski RE, Nasr M, Buhse LF, Al-Hakim A, Keire DA. Anal. Bioanal.
Chem. 2011; 401:2445–2454. [PubMed: 21901459]
5. a) Petitou M, van Boeckel CAA. Angew. Chem. Int. Ed. 2004; 43:3118–3133.b) Arungundram S,
Boons GJ. J. Am. Chem. Soc. 2009; 131:17394–17405. [PubMed: 19904943] c) Wang Z, Xu Y,
Yang B, Tiruchinapally G, Sun B, Liu R, Dulaney S, Liu J, Huang X. Chem. Eur. J. 2010; 16:8365–
8375. [PubMed: 20623566] d) Hu Y–P, Lin S–Y, Huang C–Y, Zulueta MML, Liu J–Y, Chang W,
Huang S–C. Nat. Chem. 2011; 3:557–563. [PubMed: 21697878] e) Cai C, Solakyildirim K, Yang
B, Beaudet JM, Weyers A, Linhardt RJ, Zhang F. Carbohydrate Polymers. 2012; 87:822–829.
[PubMed: 22140285]
6. a) Kuberan B, Lech MZ, Beeler DL, Wu ZL, Rosenberg RD. Nat. Biotechnol. 2003; 21:1343–1346.
[PubMed: 14528313] b) Lindahl U, Li JP, Kusche-Gullberg M, Salmivirta M, Alaranta S, Veromaa
T, Emeis J, Roberts I, Taylor C, Oreste P, Zoppetti G, Naggi A, Torri G, Casu B. J. Med. Chem.
2005; 48:349–352. [PubMed: 15658847]
7. a) Xu Y, Masuko S, Takieddin M, Xu H, Liu R, Jing J, Mousa S, Linhardt RJ, Liu J. Science. 2011;
334:498–501. [PubMed: 22034431] b) Masuko S, Linhardt RJ. Future Med. Chem. 2012; 4:289–
296. [PubMed: 22393937] c) Masuko S, Bera S, Green DE, Weïwer M, Liu J, DeAngelis PL,
Linhardt RJ. J. Org. Chem. 2012; 77:1449–1456. [PubMed: 22239739]
8. DeAngelis PL, Liu J, Linhardt RJ. Glycobiology. 2013
9. a) Minakuchi H, Nakanishi K, Soga N, Ishizuka N, Tanaka N. Anal. Chem. 1996; 68:3498–3501.
[PubMed: 21619283] b) Kerns RJ, Linhardt RJ. J. Chromatogr. A. 1995; 705:369–373. [PubMed:
7640772]
10. a) Fukase K, Yasukochi T, Nakai Y, Kusumoto S. Tetrahedron Lett. 1996; 37:3343–3344.b)
Fukase K, Yasukochi T, Suda Y, Yoshida M, Kusumoto S. Tetrahedron Lett. 1996; 37:6763–6766.
11. a) Vaxelaire C, Souquet F, Lannou M, Ardisson J, Royer J. Eur. J. Org. Chem. 2009; 2009:3138–
3140.b) Fukase K, Egusa K, Nakai Y, Kusumoto S. Mol. Divers. 1996; 2:182–188. [PubMed:
9249753]
12. Reverse phase C-18 flash column: 2% acetonitrile aqueous solution containing 0.1% TFA elute the
enzyme, salt and UTP etc. 70% acetonitrile aqueous solution with 0.1% TFA elute the product
with p-NP tag.
13. UDP-GlcNTFA was chemoenzymatically synthesized as described in Ref. 7c. Expression of
enzyme including KfiA, pmHS2, NST and chemoenzymatic reactions were all handled as
described in Ref. 7a.
14. a) Hajipour AR, Khazdooz L, Ruoho AE. J. Iran. Chem. Soc. 2011; 8:382–387.b) Maverick AW,
Yao Q. Inorg. Chem. 1993; 32:5626–5628.
Cai et al. Page 4













15. General experimental procedure for the synthesis of compounds 10 and 11. To the freshly prepared
solution of THF/H2O/acetic anhydride (4:5:1, 1 mL), 10% Pd(OH)2/C (w/w, 2 mg) and compound
9 (1.31 mg, 1.0 µmol) were added without special exclusion of air or moisture. The mixture was
stirred under a hydrogen atmosphere at room temperature for 1.5 h, and progress of the reaction
was monitored by TLC (HCOOH/BuOH/H2O, 4/8/1, Rf = 0.36). The mixture was filtered through
a thin pad of Celite, which was subsequently washed with water (5 mL). The solvent was removed
by rotary evaporation to yield 10 (1.28 mg, 94%). Compound 10 (1.28 mg, 0.94 µmol) was
dissolved in 940 µL H2O which was subsequently added 5 mM CAS aqeous solution (940 µL) at 0
°C. The mixture was stirred for 0.5 h, and progress of the reaction was monitored by TLC
(HCOOH/BuOH/H2O, 4:8:1, Rf = 0.31). The product was subjected on Biogel P-2
chromatography (1.0 × 60 cm) which was equilibrated with 0.1 M ammonium bicarbonate at a
flow rate of 25 ml/h. The fraction containing the product was lyophilized to yield 11 (1.02 mg,
89%).
16. Spectroscopic data for compounds 9–11. Compound 9: 1H NMR (800 MHz, D2O): δ 8.14 (d, 1 H,
J = 9.2 Hz), 7.11 (d, 1 H, J = 9.2 Hz), 5.63 (d, 1 H, J = 3.5 Hz, H-1A), 5.58 (d, 1 H, J = 3.4 Hz,
H-1C), 5.55 (d, 1 H, J = 3.6 Hz, H-1E), 5.23 (d, 1 H, J = 7.8 Hz, H-1F), 4.46 (d, 1 H, J = 7.9 Hz,
H-1B), 4.44 (d, 1 H, J= 7.8 Hz, H-1D), 4.36-4.26 (m, 3 H), 4.24-4.16 (m, 2 H), 4.14 (s, 2 H),
4.04-3.97 (m, 1 H), 3.95 (d, 1 H, J = 9.7 Hz), 3.91 (t, 1 H, J = 9.3 Hz), 3.89-3.84 (m, 2 H),
3.84-3.77 (m, 4 H), 3.78-3.73 (m, 4 H), 3.72-3.65 (m, 3H), 3.64-3.58 (m, 3 H), 3.52-3.47 (m, 1 H),
3.41 (t, 1 H, J = 9.7 Hz), 3.35 (t, 1 H, J = 9.2 Hz), 3.33 (t, 1 H, J =8.3 Hz), 3.24 (dd, 1 H, J= 3.6,
10.6 Hz), 3.22 (dd, 1 H, J= 3.9, 9.9 Hz), 3.19 (dd, 1 H, J= 4.0, 10.2 Hz); 13C NMR (200 MHz,
D2O): δ 102.2 (C-1B, C-1D), 99.5 (C-1F), 96.9 (C-1C, C-1E), 95.1 (C-1A), 83.9, 83.1, 77.6, 76.6,
76.3, 75.8, 73.8, 73.1, 72.6, 72.2, 70.3, 70.2, 69.8, 69.4, 68.9, 65.1, 64.9, 64.4, 63.8, 63.4, 59.6,
59.3, 57.6, 54.5, 54.2. HRMS-FAB: [M−H]− m/z calcd. for C42H62N4O39S2, 1309.2354; found:
1309.2366. Compound 10: 1H NMR (800 MHz, D2O): δ 7.27 (d, 1 H, J = 9.0 Hz), 7.05 (d, 1 H, J
= 9.0 Hz), 5.57 (d, 1 H, J = 3.7 Hz, H-1C), 5.54 (d, 1 H, J = 4.2 Hz, H-1E), 5.34 (d, 1 H, J = 3.6
Hz, H-1A), 5.05 (d, 1 H, J = 8.0 Hz, H-1F), 4.46 (d, 1 H, J = 7.8 Hz, H-1B), 4.43 (d, 1 H, J = 7.9
Hz, H-1D), 4.41 (d, 1 H, J = 7.6 Hz), 4.36-4.34 (m, 1 H), 4.32-4.30 (m, 1 H), 4.29-4.28 (m, 2 H),
4.22-4.13 (m, 4H), 4.00-3.96 (m, 1 H), 3.94-3.91 (m, 1 H), 3.87 (t, 2 H, J = 7.5 Hz), 3.82-3.78 (m,
3 H), 3.77-3.75 (m, 2 H), 3.75-3.71 (m, 3 H), 3.70-3.64 (m, 3 H), 3.63-3.58 (m, 4 H), 3.54 (t, 1 H,
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(C-1B, C-1D), 96.8 (C-1C, C-1E), 96.7 (C-1A), 95.8 (C-1βF), 91.7 (C-1αF), 77.6, 76.6, 76.2, 75.7,
73.3, 72.6, 71.7, 70.5, 70.2, 70.1, 69.3, 69.2, 59.9, 59.8, 59.1, 57.2, 53.4. HRMS-FAB: [M−H]− m/
z calcd. for C38H60N3O38S2, 1230.2296; found: 1230.2312.
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NMR characterization of heparan sulfate oligosaccharides. Panel I shows the 1D 1H NMR
spectrum of compound 9 (R1 = p-NP, R2 = H). Panel II shows the 1D 1H NMR spectrum of
compound 11 (R1 = H, R2 = Ac). Peaks corresponding to the anomeric protons of these
compounds can be clearly identified. Panel III shows the selected anomeric carbon region
(91 ppm to 103 ppm) in 2D 1H-13C HMQC spectrum of compound 11.
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Backbone construction of HS oligosaccharides
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Deprotection of p-NP group with ceric ammonium nitrate
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Deprotection of p-NP with ceric ammonium sulfate on HS oligosaccharide
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Deprotection of p-NP group with ceric ammonium sulfate
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